Two Pivotal Readouts This Year With Midyear Data to Define U.S. Potential; Expanding Beyond HCV With Upcoming HEV Trial

Research evidence excerpt

Two Pivotal Readouts This Year With Midyear Data to Define U.S. Potential; Expanding Beyond HCV With Upcoming HEV Trial

olves risks. This report does not contain all the material information necessary for an

investment decision. Always refer to the most recent report on a company or issuer. Our asset management and trading desks may make

investment decisions that are inconsistent with recommendations or views expressed in this report. We will from time to time have long

or short positions in, act as principal in, and buy or sell the securities referred to in this report. Our research is disseminated primarily

electronically, and in some instances in printed form. Research is simultaneously available to all clients. This research report is for our clients

only. No part of this material may be copied or duplicated in any form by any means or redistributed without the prior written consent of

William Blair & Company, L.L.C.

This is not in any sense an offer or solicitation for the purchase or sale of a security or financial instrument.

The factual statements herein have been taken from sources we believe to be reliable, but such statements are made without any

representation as to accuracy or completeness or otherwise, except with respect to any disclosures relative to William Blair or its research

analysts. Opinions expressed are our own unless otherwise stated and are subject to change without notice. Prices shown are approximate.

This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient to any third party, by

content scraping or extraction, automated processing, or any other form or means, without the prior written consent of William Blair. Any

unauthorized use is prohibited.